, † Adenosine is a key endogenous signaling molecule that regulates a wide range of physiological functions, including immune system function and inflammation. Studies have shown that adenosine receptor (AR) agonists can be either anti-inflammatory or proinflammatory in immune responses and in inflammation, and the clarification of the mechanisms causing these opposing effects should provide a better guide for therapeutic intervention. Whereas previous studies mostly examined the effects of AR agonists on Th1-type immune responses, in this study, we compared their effect on Th17 and Th1 autoimmune responses in experimental autoimmune uveitis, a mouse model of human uveitis induced by immunization with the human interphotoreceptor retinoidbinding protein peptides [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . We showed that injection of mice with a nonselective AR agonist, 59-N-ethylcarboxamidoadenosine (NECA), at an early stage after immunization had an inhibitory effect on both Th1 and Th17 responses, whereas injection of the same amount of NECA at a late stage inhibited the Th1 response but had an enhancing effect on the Th17 response. We also showed that the effects of NECA on Th1 and Th17 responses were completely dissociated, that the enhancing effect of NECA on Th17 responses was modulated by gd T cells, and that the response of gd T cells to NECA was determined by their activation status. We conclude that the inflammatory environment has a strong impact on converting the effect of AR agonist on the Th17 autoimmune response from anti-inflammatory to proinflammatory. Our observation should help in the designing of better ARtargeted therapies. The Journal of Immunology, 2014, 193: 5498-5505. P revious studies have shown that the appropriate generation and clearance of extracellular accumulated adenosine in inflammation are critical in limiting tissue pathology (1) (2) (3) (4) . Experimental studies have shown that adenosine receptor (AR) agonists and antagonists are promising pharmacological modulators of disease-associated inflammation and immune responses (5-10), but it has been difficult to achieve reproducible beneficial effects because of a lack of knowledge of how adenosine exerts anti-inflammatory or proinflammatory effects (11) (12) (13) . Previous studies have proposed that the pro-inflammatory and antiinflammatory effects of adenosine are produced by activation of different ARs. For example, the suppressive effects of adenosine are mainly mediated by A2A receptor (A2AR) signaling (14) (15) (16) , whereas A2B receptor (A2BR) signaling mostly enhances immune responses (13, (17) (18) (19) (20) . However, this cannot explain the observations that A2AR 2/2 mice show increased susceptibility to autoimmune disease and that administration of an A2AR antagonist to mice with actively induced experimental autoimmune encephalomyelitis (EAE) inhibits, rather than enhances, disease development (21) , implying that whether an AR agonist is anti-inflammatory or proinflammatory is sophisticatedly regulated. To identify factors that modulate or convert the enhancing and inhibiting effects of AR agonists, we asked whether T cell subsets at different degrees of activation respond differently to the same AR agonist and whether environmental factors modulate the antiinflammatory and proinflammatory effects of an AR agonist. Because previous studies examining the effect of AR agonists on immune responses have mainly looked at the IFN-g-producing (or Th1) cell response, and because our ongoing study of the regulation of the Th17 autoimmune response in experimental autoimmune uveitis (EAU) showed that gd T cells have a strong regulatory effect on Th17 autoreactive T cells (22) (23) (24) (25) and that these cells express high levels of ARs (26), we asked whether AR agonists affect the Th1 and Th17 responses differently and whether the regulation of the Th17 autoimmune response by AR agonists is associated with the regulatory activity of gd T cells in the Th17 response. In this study, using a mouse model of uveitis in which B6 mice are immunized with the human interphotoreceptor retinoid-binding protein (IRBP) peptide IRBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] to induce EAU, thus promoting the in vivo activation of Th1 and Th17 autoreactive T cells (22, 25, 27, 28) , we showed that, although AR agonists always had an inhibitory effect on the Th1 autoimmune response, their effect on the Th17 autoimmune response could be either inhibitory or enhancing, depending on both environmental conditions and the activation status of the T cells. A single early injection of the immunized mice (days 0-5 after immunization with IRBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] with an AR agonist had a suppressive effect on the Th17 response, whereas treatment at a later date (days 7-10 postimmunization), when inflammation had already been initiated, had an enhancing effect on the Th17 response. Mechanistic studies showed that the enhancing effect of an AR agonist required the presence of gd T cells and was greatly diminished when the gd T cells were functionally deficient. Moreover, an enhancing effect was only seen for Th17 responses. Our observation that the proinflammatory and anti-inflammatory effects of an AR agonist can be converted by environmental factors implies that successful ARtargeting treatments or immunomodulation requires monitoring of existing environmental conditions.
Materials and Methods
All animal studies conformed to the Association for Research in Vision and Ophthalmology statement on the use of animals in Ophthalmic and Vision Research. Institutional approval was obtained from the Institutional Animal Care and Use Committee of the Doheny Eye Institute, University of Southern California, and institutional guidelines regarding animal experimentation were followed.
Animals and reagents
Female C57BL/6 (B6) and TCR-d 2/2 mice on the B6 background, purchased from The Jackson Laboratory (Bar Harbor, ME), were housed and maintained in the animal facilities of the University of Southern California. Recombinant murine IL-1, IL-7, and IL-23 were purchased from R&D Systems (Minneapolis, MN). FITC-or PE-conjugated Abs against the mouse ab TCR, gd TCR, IL-17, IFN-g, or CD44 and isotype control Abs were purchased from Biolegend (San Diego, CA). The nonselective AR agonist 59-N-ethylcarboxamidoadenosine (NECA), the selective A2AR agonist 2-p-(2-carboxyethyl) phenethylamino-NECA (CGS21680), and the selective A2BR agonist (BAY 60-6538) were purchased from SigmaAldrich (St. Louis, MO).
Immunization and NECA treatment EAU was induced in B6 mice by s.c. injection of 200 ml emulsion containing 200 mg human IRBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] (Sigma-Aldrich) in CFA (Difco, Detroit, MI) at six spots at the tail base and on the flank, and by i.p. injection with 300 ng pertussis toxin, as described previously (23, 25, 28) .
For NECA treatment, immunized B6 mice received a single i.p. injection of NECA (5 mg/kg) on different days after immunization; the day of injection was day 0 (early) or 7 (late) postimmunization. Controls were injected with vehicle only.
T cell preparation
ab and gd T cells were purified from B6 mice immunized with IRBP 1-20 as described previously (22, 25, 28) . Nylon wool-enriched splenic T cells were incubated sequentially for 10 min at 4˚C with FITC-conjugated antimouse gd TCR or ab TCR Abs and for 15 min at 4˚C with anti-FITC Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany); then the cells were separated into bound and nonbound fractions on an autoMACS separator column (Miltenyi Biotec). The purity of the isolated cells, determined by flow cytometric analysis using PE-conjugated Abs against ab or gd T cells, was .95%.
Assessment of Th1 and Th17 polarized responses
Responder T cells (3 3 10 6 ) prepared from IRBP 1-20 -immunized B6 or TCR-d 2/2 mice were cocultured for 48 h with IRBP 1-20 (10 mg/ml) and irradiated spleen cells (2 3 10 6 /well) as APCs in a 12-well plate under either Th17 polarized conditions (culture medium supplemented with 10 ng/ml IL-23) or Th1 polarized conditions (culture medium supplemented with 10 ng/ml IL-12); then IL-17 and IFN-g levels in the culture medium were measured using ELISA kits (R&D Systems), and the number of Ag-specific T cells expressing IL-17 or IFN-g was determined by intracellular staining followed by FACS analysis.
Cytoplasmic staining
After 5 d of in vitro stimulation of the in vivo primed T cells with the immunizing Ag and APCs, activated T cells were separated using Ficoll gradient centrifugation and stimulated in vitro for 4 h with 50 ng/ml PMA, 1 mg/ml ionomycin, and 1 mg/ml brefeldin A (Sigma-Aldrich). The cells were then fixed, permeabilized overnight with Cytofix/Cytoperm buffer FIGURE 1. NECA treatment can either suppress or enhance the Th17 response in mouse EAU. Groups of B6 mice were immunized with IRBP 1-20 /CFA alone or were also injected with NECA (100 ng/mouse) either on the day of immunization (early treatment) or 7 d after immunization (late treatment). All the mice were euthanized 13 d postimmunization, sera were collected, and T cells from the draining lymph nodes and spleens were separated, counted, and subjected to in vitro stimulation with an optimal dose of immunizing peptide (10 mg/ml) and APCs (irradiated spleen cells) in medium supplemented with 10 ng/ml IL-23; then the activated T cells were separated on a Ficoll gradient and subjected to various analyses. Results shown [except in (B) ] are the mean 6 SD for one study using four mice, and the experiment was repeated four to five times with similar results. (eBioscience, San Diego, CA), and intracellularly stained with Abs against IFN-g or IL-17 and analyzed on a FACSCalibur.
Immunofluorescence flow cytometry
Aliquots of 2 3 10 5 cells were double-stained with combinations of FITCor PE-conjugated mAbs. Data collection and analysis were performed on a FACSCalibur flow cytometer using CellQuest software.
Limiting dilution analysis

B6 and TCR-d
2/2 mice immunized with IRBP 1-20 /CFA were left untreated or were injected with NECA; then the spleen and draining lymph nodes were removed 13 d after immunization and pooled, and a single-cell suspension prepared. T cells were enriched by MACS column purification and seeded in 24 replicates in 2 sets of 96-well flat-bottom culture plates containing irradiated spleen cells (1 3 10 5 per well) under Th1 or Th17 polarizing conditions, with one set of plates containing an optimal dose of immunizing peptide (10 mg/ml). Based on preliminary limiting dilution assay (LDA) estimates of frequencies, the number of T cells seeded in each well varied from 3 3 10 3 to 2 3 10 5 . After 44 h of incubation, the plates were pulsed with 0.5 mCi [ 
Induction of EAU by cell transfer
For induction of EAU by adoptive transfer, T cells were isolated from lymph node and spleen cells on days 12-14 postimmunization (optimal time for proliferation and cytokine responses) and stimulated for 48 h with 10 mg/ml IRBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] in the presence of irradiated syngeneic APCs; then activated T cell blasts were separated by Ficoll gradient centrifugation and transferred into B6 mice (1.5 3 10 6 activated cells/mouse).
Scoring of EAU
The mice were examined three times a week for clinical signs of EAU by indirect funduscopy. The pupils were dilated using 0.5% tropicamide and 1.25% phenylephrine hydrochloride ophthalmic solutions, and funduscopic grading of disease was performed using the scoring system described previously (32) . For histopathological evaluation, whole eyes were collected at the end of the experiment and immersed for 1 h in 4% glutaraldehyde in phosphate buffer, pH 7.4, then transferred to 10% formaldehyde in phosphate buffer until processed. The fixed and dehydrated tissues were embedded in methacrylate, then 5-mm sections were cut through the pupillary-optic nerve plane and stained with H&E. Presence or absence of disease was evaluated blind by examining six sections cut at different levels for each eye. Disease was graded pathologically based on cellular infiltration and structural changes (33) .
Assessment of the gd T cell response to AR agonists
gd T cells were isolated from naive or immunized B6 mice using a MACS column, then 5 3 10 4 /well separated gd T cells were cultured for 48 h in 96-well plates in medium with or without NECA (100 ng/ml), and the supernatants were collected for assessment of IL-17 levels.
Assessment of the enhancing effect of gdTCR + T cells on Th17 autoreactive T cells ab T cells (1 3 10 6 ) from immunized TCR-d 2/2 mice were stimulated with the immunizing peptide in 24-well plates for 5 d in the presence or absence of gd T cells (5% of total cell number) isolated from immunized B6 mice that had either been left untreated or had been incubated for 48 h with 100 nM NECA; then the proliferating cells were separated on a Ficoll gradient, intracellularly stained with anti-IL-17 Abs, and subjected to FACS analysis.
Statistical analysis
Experiments were repeated four to five times. Experimental groups were typically composed of four mice, and the figures show the data from a representative experiment. The statistical significance of differences between the values for different groups was examined using the two-tailed Student t test.
Results
Whether an AR agonist has an anti-inflammatory or proinflammatory effect in mice with actively induced EAU depends on whether it is administered before or after onset of inflammation To examine the effect of an AR agonist on the Th17 autoimmune response and whether this was affected by the time of injection of the agonist, we immunized B6 mice with the uveitogenic peptide IRBP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] in CFA, then randomly divided them into three groups (n = 4). One group received an i.p. injection of 100 ng/mouse NECA, a nonselective AR agonist (13) that binds to both A2ARs and A2BRs, during the early stage after IRBP 1-20 immunization (days 0-5); another group was treated with NECA 7-10 d after immunization; and the third group was left untreated. A kinetic study of the effects of NECA administration at different time points showed a change in effect from anti-inflammatory to proinflammatory at days 6-7 (data not shown); therefore, in subsequent studies, two representative time points were used, with the agonist being injected on day 0 (during immunization), designated as "early treatment," or on day 7 after immunization, designated as "late treatment." At day 13 after immunization (the time point at which the highest T cell response is seen), serum cytokine levels were measured and responder T cells from the spleens and draining lymph nodes were subjected to in vitro stimulation with the immunizing peptide (10 mg/ml) and APCs (irradiated spleen cells) under culture conditions that favor Th17 autoreactive T cell expansion (medium containing 10 ng/ml IL-23) (25, 29, 34) , and the activated T cell blasts separated by Ficoll gradient centrifugation and stained intracellularly with FITC-labeled anti-IL-17 Abs. Fig. 1 shows that the responses of T cells from mice that received NECA treatment differed greatly from those of T cells from untreated mice, being either inhibited or enhanced, depending on the time point when NECA was injected. Fig. 1A shows that serum IL-17 levels were reduced by early NECA treatment and increased by late treatment. Intracellular staining of in vitro-stimulated, IRBPspecific T cells showed that late treatment resulted in a significantly higher percentage of IL-17 + ab T cells (Th17 response) than in mice not treated with NECA, whereas early treatment resulted in a significantly depressed Th17 response compared with control mice (Fig. 1B, 1C) . Measurement of secreted IL-17 levels showed that responder T cells from late-treatment mice produced much higher levels of IL-17 than T cells from non-NECA-treated mice, whereas cells from early-treatment mice produced minimal amounts of IL-17 (Fig. 1D) . We also performed LDA, which measures the frequency of in vivo primed Ag-specific Th17 cells before in vitro expansion (25, 29, 34) . As shown in Fig. 1E , the frequency of in vivo primed IL-17 + IRBP 1-20 -specific T cells was significantly increased in late-treatment mice (.40 per 100,000 responder T cells compared with 22 in controls) and significantly decreased in early-treatment mice (,5 per 100,000 responder T cells). We also compared the pathogenic activity of the Th17 polarized cells derived from the different groups of mice. Our results showed that the number of IRBP 1-20 -specific Th17 cells in late-treatment mice was significantly higher (2.5 3 10 6 /mouse) than that in non-NECA-treated mice (1.0 3 10 6 /mouse) and was reduced in early-treatment mice (0.4 3 10 6 /mouse; Fig. 2A ). Moreover, as shown by funduscopy (Fig. 2B ) and pathological examination (Fig. 2C) , when 1.5 3 10 6 activated IRBP-specific T cells were adoptively transferred into naive mice by i.p. injection, the induced EAU was significantly more severe using cells from late-treatment mice than using cells from control mice, whereas no disease was seen using cells from the early-treatment group, demonstrating that the late-treatment mice generated more IL-17 + pathogenic T cells.
Comparison of the effect of selective and nonselective AR agonists
Because NECA nonselectively binds to all four types of ARs, we examined whether the effect was mediated via a specific AR. Groups of B6 mice were immunized with IRBP/CFA and either left untreated or injected on day 0 or 7 with an agonist specific for A2ARs (CGS 21680, 1 mg/kg body weight), A2BRs (BAY 60-6538), or the nonselective NECA; then on day 13, serum IL-17 levels (Fig. 3A) , the percentage of proliferating IL-17 + cells among the in vitro-stimulated T cells (Fig. 3B, 3C) , and IL-17 production by the responder T cells after in vitro stimulation (Fig. 3D) were measured. The results showed that the A2AR agonist (CGS21680) and NECA had a similar inhibitory effect on Th17 responses compared with the nonagonist-treated group in the early-treatment group, but a stimulatory effect in the late-treatment group. In contrast, the A2BR agonist caused a moderate increase in the Th17 responses regardless of the time of treatment, suggesting that the nonselective agonist NECA mainly acts via A2ARs, which can exert either an enhancing or an inhibitory effect on the Th17 response.
Differential effects of an AR agonist on Th1 and Th17 responses
To determine whether AR agonists have the same or a different effect on different types of responder T cells, we also examined the effect of NECA on Th1 responses. First, we measured serum IFN-g levels at day 13 in immunized mice with or without early or late NECA treatment. As shown in Fig. 4A , both sets of NECA-treated mice produced significantly less IFN-g and, as shown in Fig. 4B , the frequency of in vivo primed IFN-g-producing cells was also significantly decreased in both sets of NECA-treated mice. After stimulation with the immunizing peptide under Th1-polarized conditions in vitro, IFN-g production (Fig. 4C ) and the number of IFN-g-expressing cells (Fig. 4D) were both significantly decreased in both sets of NECA-treated mice, although late treatment had less of an inhibitory effect. These results contrast markedly with the effect on the Th17 responses shown in Fig. 1 .
Effect of an AR is modulated by gd T cells
We recently reported that activation of gd T cells plays a key role in the activation and expansion of a Th17 autoimmune response (22) (23) (24) (25) . To determine whether the effect of an AR agonist on ab T cells in the in vitro Ag-stimulated T cells (Fig. 5C) , and lower IL-17 production by in vitro Ag-stimulated T cells (Fig. 5D) , showing that the enhancing effect of late treatment with an AR agonist on Th17 responder T cells requires a gd T cell response.
gd T cells from immunized mice respond more vigorously to NECA than gd T cells from naive mice
To further examine a possible role of gd T cells in the immunomodulatory effect of NECA in EAU, we determined the effect of in vivo early or late injection of NECA on gd T cell activation in IRBP 1-20 -immunized B6 mice on day 13 after immunization. As shown in Fig. 6A , only 1.8% of total CD3 + splenic T cells in naive mice were gd T cells, whereas the corresponding numbers were 7.0% in non-NECA-treated immunized mice, 4.9% in immunized mice with early NECA treatment, and 10% in late NECA treatment mice. In addition, the percentage of gd T cells expressing the T cell activation molecule CD44 was 5.1% in naive mice and 32% in immunized non-NECA-treated mice, and this percentage declined to 18% with early NECA treatment and increased to 63% with late NECA treatment (Fig. 6A) , paralleling the effect on the Th17 response. To determine whether the activation status of gd T cells had an effect on the enhancing effect of the AR agonist on Th17 response in immunized mice, we compared the effect of in vitro NECA treatment (100 nM) on gd T cells separated from naive and immunized mice. As shown in Fig. 6B , gd T cells isolated from naive mice produced little IL-17 after incubation for 48 h in medium with or without NECA, whereas gd T cells isolated from immunized mice produced moderate amounts of IL-17 in the absence of NECA, and levels were significantly enhanced by culture in medium with NECA. Finally, we performed a study in which the percentage of IL-17 + T cells was measured among responder T cells from immunized TCR-d 2/2 mice after 5 d of in vitro stimulation in the absence or presence of gd T cells (5% of the total cell number) from immunized B6 mice that had been either left untreated or had been stimulated for 48 h in vitro with NECA. The results showed that NECA-treated gd T cells were much more effective than untreated gd T cells in increasing the percentage of IL-17 + ab T cells (Fig. 6C ).
Discussion
Previous studies have shown that adenosine can either inhibit or enhance an immune response, depending on which of the four identified ARs (35) is/are activated (13) (14) (15) (16) (17) (18) (19) (20) . In general, activation of A2ARs has anti-inflammatory effects (15, 16, 36, 37) , whereas activation of A2BRs promotes inflammatory responses (11, 18, 38) . However, this does not apply to all immune responses. For example, proinflammatory effects have been seen as a result of A2AR activation (11, 18) , and anti-inflammatory effects of A2BR activation have been reported (11, (39) (40) (41) . A study in A2AR 2/2 mice showed that they developed more severe EAE than syngeneic B6 mice, but treatment of wild-type B6 mice with an A2AR antagonist inhibited, rather than enhanced, the development of EAE (21), suggesting that the mechanisms by which adenosine agonists/antagonists affect an immune response is more sophisticated than currently thought. Because AR-based treatments have been promoted for the treatment of autoimmune diseases (7-9) and neurological diseases (10) and in transplantation (42), clarification of the mechanisms involved will help determine how to use such molecules for immune modulation.
Early studies investigating the effect of adenosine on T cell biology mostly examined the response of IFN-g-producing (Th1-type) T cells, so we were interested in determining whether AR agonists are also able to manipulate Th17 pathogenic autoimmune responses in EAU, and whether Th1 and Th17 autoreactive T cells respond similarly to AR agonists. Using our recently established system for studying the role of gd T cells in Th17 autoimmune responses (22) (23) (24) (25) , we examined whether AR agonists exert their effect by acting http://www.jimmunol.org/ on gd T cells, leading to altered Th17 responses. We found that injection of mice with actively induced EAU with a nonspecific AR agonist during the inducing phase had a suppressive effect, whereas AR agonist injection when autoimmune inflammation had already been initiated (7-10 d postimmunization) enhanced the pathogenic response. A study using agonists specific for A2ARs or A2BRs showed that A2AR activation had the strongest modulating effect on the Th17 autoimmune response. Kinetic studies showed that the inhibitory effect was seen when the agonist was injected during the first week of disease induction, whereas later administration enhanced the response (data not shown). We also demonstrated that the enhancing effect of late AR agonist treatment on the Th17 response was markedly reduced in TCR-d 2/2 mice lacking gd T cells, suggesting that the functional conversion requires the involvement of gd T cells. These observations support our previous reports that gd T cells play an important role in the Th17 autoimmune response and that activation of gd T cells converts their effect on Th17 responses from anti-inflammatory to proinflammatory (23, 43) . Our present finding also suggests that excessive production of adenosine may enhance the in vivo activation of gd T cells and Th17 autoreactive T cells. We demonstrated that, regardless of treatment time, an AR agonist consistently suppressed Th1 responses, whereas it either enhanced or suppressed the Th17 response, depending on the status of autoimmune inflammation. This unique effect of an AR agonist on Th17 responses is conceivably related to a synergistic effect on gd T cell activation of adenosine and proinflammatory molecules, such as cytokines and TLR ligands, which preferentially promotes Th17, but not Th1, responses, as shown in our previous studies (22, 23, 25, 28) . In this study, we also showed that gd T cells with different activation status varied significantly in their response to an AR agonist. These results show that, in attempts at manipulating inflammation and the immune response using AR agonists or antagonists, we should take into consideration this two-edged sword effect of adenosine on the Th17 response. An AR agonist might exert a strong suppressive effect on the immune response during the quiescent phase of the disease, but this effect can be converted from anti-inflammatory effect to proinflammatory when the agonist is applied during ongoing disease when inflammation has already occurred. The fact that exogenously administered AR agonists have a different effect on Th1 and Th17 immune responses suggests caution in their use in the treatment of diseases involving both Th1 and Th17 responses.
The different effects of AR agonist on Th1 and Th17 responses involve several immune cells, including gd, ab T cells, and DCs. In a recent article, we have demonstrated that gd T cells from immunized mice expressed the highest levels of A2AR and possess the strongest binding ability to adenosine, as compared with other immune cells examined, including ab T cells, DCs, and B cells. A very small (3%) number of the activated gd T cells can effectively compete adenosine binding with a majority (97%) of the cocultured ab T cells. Binding of adenosine by gd T cells not only diminishes the suppressive effect of adenosine on ab T cells, but also promotes gd T cell activation, rendering these cells more competitive in adenosine binding (26) . To further clarify the mechanisms by which AR agonist regulate autoimmune responses, we have examined the AR agonist effect on DCs and gd-DC interactions. We have elsewhere (D. Liang, A. Zuo, H. Shao, H. Kaplan, and D. Sun, manuscript in preparation) demonstrated that adenosine promoted the differentiation of a DC subset coexpressing CD11c and Gr-1, which possess a strong stimulating effect on Th17 autoreactive T cells. We have also determined the effect of NECA treatment on Foxp3 + regulatory cells. Our results did not show a significant effect or a change in number of Foxp3 + cells.
In vivo, T cells are exposed to a complex of cytokines, TLR ligands, and adenosine metabolites, particularly in an inflammatory environment, and display considerable functional plasticity. Recent studies have shown that the activity of regulatory T cells can be reduced in response to environmental triggers, a process designated as "instability of regulatory T cell function" (44) (45) (46) (47) . Our results provide support for this by showing that, as one of the major regulatory T cells in the Th17 autoimmune response (22, 23, 25, 28) , gd T cell function was also modulated by inflammatory factors. Adenosine is produced under various stress conditions (37, (48) (49) (50) (51) and exerts multifaceted effects on various functions, including that of the immune system, and its effect on immune responses deserves further examination.
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